Shinobi Therapeutics key facts
- Developer of cell therapies designed for comprehensive immune evasion.
- It has raised $78.3M; the latest was Grant ($59.0M) in Aug 2024.
- Notable investors include Mitsubishi UFJ Capital, F-Prime Capital, Eight Roads, JIC Venture Growth Investments, Kyoto University Innovation Capital — 10 tracked in total.
- Status: Privately Held (backing).
Shinobi Therapeutics leadership
- Donald PayanFounder
- Luis BorgesChief Scientific Officer
- Ryosuke GonotsuboChief Executive Officer & Chief Financial Officer
- Steven KatzChief Medical Officer
- ·Watch Shinobi Therapeutics: the Monday email on marks, rounds and moves
Shinobi Therapeutics funding rounds
No funding rounds for Shinobi Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Shinobi Therapeutics investors
10 investors are on record for Shinobi Therapeutics, including Mitsubishi UFJ Capital, F-Prime Capital, Eight Roads and JIC Venture Growth Investments. By type, the record holds 4 venture capital firms and 1 asset manager.
Who runs Shinobi Therapeutics
14 people are listed on the Shinobi Therapeutics team: 5 executives, 7 board members and 2 advisors and observers, including Donald Payan (Founder) and Ryosuke Gonotsubo (Chief Executive Officer). 14 of them have a verified direct contact on file.
About Shinobi Therapeutics
Developer of cell therapies designed for comprehensive immune evasion. The company is developing a new class of hyperimmune CD8ab iPS-T cells for cancer and other genetic diseases, providing the healthcare industry with immune therapies to treat diseases.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2015
- Employees
- 37
- Website
- shinobitx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Shinobi Therapeutics doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.